Quine Biologics, Inc.
Quine Biologics aims to revolutionize healthcare and biotechnology by developing bespoke AI-designed antibodies and mimetics for any protein target. Their mission is to meet the demand for personalized medicine using cutting-edge AI technology, providing custom antibody solutions that enable researchers and clinicians with precise tools to address complex diseases and advance immunotherapies. The company leverages deep learning, artificial intelligence, and high-performance computing to design therapeutic-grade antibodies specific to protein targets. Utilizing SE(3) denoising diffusion, they can create antibody complementary determining region (CDR) designs directly into the epitope of interest, resulting in faster and more cost-effective lead antibody candidate design compared to traditional methods.
Quine Biologics, Inc.
Quine Biologics aims to revolutionize healthcare and biotechnology by developing bespoke AI-designed antibodies and mimetics for any protein target. Their mission is to meet the demand for personalized medicine using cutting-edge AI technology, providing custom antibody solutions that enable researchers and clinicians with precise tools to address complex diseases and advance immunotherapies. The company leverages deep learning, artificial intelligence, and high-performance computing to design therapeutic-grade antibodies specific to protein targets. Utilizing SE(3) denoising diffusion, they can create antibody complementary determining region (CDR) designs directly into the epitope of interest, resulting in faster and more cost-effective lead antibody candidate design compared to traditional methods.